| DE vs ABC calls (RNA-seq vs HTG EdgeSeq), n = 705 . | ||||
|---|---|---|---|---|
| Subtypes, n (%) . | DE, n = 217 . | OR (95% CI) . | P value . | Non-DE, n = 488 . |
| ABC | 193 (88.9) | 3.26 (2.02-5.45) | <.0001 | 347 (71.1) |
| GCB/unclassified | 24 (11.1) | - | - | 141 (28.9) |
| DE vs ABC calls (RNA-seq vs HTG EdgeSeq), n = 705 . | ||||
|---|---|---|---|---|
| Subtypes, n (%) . | DE, n = 217 . | OR (95% CI) . | P value . | Non-DE, n = 488 . |
| ABC | 193 (88.9) | 3.26 (2.02-5.45) | <.0001 | 347 (71.1) |
| GCB/unclassified | 24 (11.1) | - | - | 141 (28.9) |
| DE vs MCD/N1/BN2 calls (RNA-seq vs LymphGen), n = 765 . | ||||
|---|---|---|---|---|
| Subtypes, n (%) . | DE, n = 234 . | OR (95% CI) . | P value . | Non-DE, n = 531 . |
| MCD | 48 (20.5) | 0.50 (0.33-0.78) | .0016 | 61 (11.5) |
| Non-MCD | 186 (79.5) | - | - | 470 (88.5) |
| N1 | 11 (4.7) | 0.67 (0.29-1.61) | .3034 | 17 (3.2) |
| Non-N1 | 223 (95.3) | - | - | 514 (96.8) |
| BN2 | 10 (4.3) | 1.63 (0.77-3.75) | .2472 | 36 (6.8) |
| Non-BN2 | 224 (95.7) | - | - | 495 (93.2) |
| DE vs MCD/N1/BN2 calls (RNA-seq vs LymphGen), n = 765 . | ||||
|---|---|---|---|---|
| Subtypes, n (%) . | DE, n = 234 . | OR (95% CI) . | P value . | Non-DE, n = 531 . |
| MCD | 48 (20.5) | 0.50 (0.33-0.78) | .0016 | 61 (11.5) |
| Non-MCD | 186 (79.5) | - | - | 470 (88.5) |
| N1 | 11 (4.7) | 0.67 (0.29-1.61) | .3034 | 17 (3.2) |
| Non-N1 | 223 (95.3) | - | - | 514 (96.8) |
| BN2 | 10 (4.3) | 1.63 (0.77-3.75) | .2472 | 36 (6.8) |
| Non-BN2 | 224 (95.7) | - | - | 495 (93.2) |
| ABC vs MCD/N1/BN2 calls (HTG EdgeSeq vs LymphGen), n = 709 . | ||||
|---|---|---|---|---|
| Subtypes, n (%) . | ABC, n = 543 . | OR (95% CI) . | P value . | GCB/unclassified, n = 166 . |
| MCD | 101 (18.6) | 0.08 (0.02-0.25) | <.0001 | 3 (1.8) |
| Non-MCD | 442 (81.4) | - | - | 163 (98.2) |
| N1 | 22 (4.1) | 0.59 (0.14-1.76) | .4785 | 4 (2.4) |
| Non-N1 | 521 (95.9) | - | - | 162 (97.6) |
| BN2 | 34 (6.3) | 1.17 (0.54-2.38) | .7186 | 12 (7.2) |
| Non-BN2 | 509 (93.7) | - | - | 154 (92.8) |
| ABC vs MCD/N1/BN2 calls (HTG EdgeSeq vs LymphGen), n = 709 . | ||||
|---|---|---|---|---|
| Subtypes, n (%) . | ABC, n = 543 . | OR (95% CI) . | P value . | GCB/unclassified, n = 166 . |
| MCD | 101 (18.6) | 0.08 (0.02-0.25) | <.0001 | 3 (1.8) |
| Non-MCD | 442 (81.4) | - | - | 163 (98.2) |
| N1 | 22 (4.1) | 0.59 (0.14-1.76) | .4785 | 4 (2.4) |
| Non-N1 | 521 (95.9) | - | - | 162 (97.6) |
| BN2 | 34 (6.3) | 1.17 (0.54-2.38) | .7186 | 12 (7.2) |
| Non-BN2 | 509 (93.7) | - | - | 154 (92.8) |
A53, aneuploid with TP53 inactivation.
Any deviations from the total number of patients in the ITT population (n = 838), the RNA-seq–surveyed subset (766 patients with DE/non-DE calls), the HTG EdgeSeq-surveyed subset (747 patients with ABC/GCB/Unclassified calls), or the subset with LymphGen calls (773 patients with MCD/N1/BN2/other calls), result from a lack of complete overlap between patients surveyed with the different assays.
A53 subtype could not be inferred as assessing aneuploidy was not allowed by methods used in the analysis.
P < .01 for the following pairwise Fisher's exact tests: DE vs MCD, DE vs ABC, and MCD vs ABC. All other Fisher's exact results had P > .20.